| Literature DB >> 27830042 |
Ming-Yi Liu1, Hsiu-Chih Tang1, Shu-Hui Hu1, Sue-Joan Chang1.
Abstract
AIM: To compare a dipeptide- and tripeptide-based enteral formula with a standard enteral formula for tolerance and nutritional outcomes in abdominal surgery patients.Entities:
Keywords: Abdominal surgery; Absorption; Dipeptides and tripeptides; Enteral nutrition; Gastric residual volume
Year: 2016 PMID: 27830042 PMCID: PMC5081552 DOI: 10.4240/wjgs.v8.i10.700
Source DB: PubMed Journal: World J Gastrointest Surg
Comparison of demographic and clinical characteristics between the whole-protein formula group and the dipeptide- and tripeptide-based formula group
| 40 | 32 | ||
| Gender (Male/Female) | 23/17 | 19/13 | 0.873 |
| Feeding route (PEG | 2/38 | 3-29 | 0.468 |
| Major diagnoses | |||
| Esophageal cancer | 4 | 5 | 0.473 |
| Colon cancer | 22 | 16 | 0.673 |
| Gastric cancer (subtotal gastrectomy) | 2 | 3 | 0.468 |
| Bile duct cancer | 4 | 2 | 0.567 |
| Ischemic bowel | 8 | 6 | 0.894 |
| Age | 67.5 ± 10.5 | 64.7 ± 10.1 | 0.263 |
| APACHE II score | 11.6 ± 2.3 | 12.4 ± 2.6 | 0.201 |
| Ventilator dependence, | 15 (37.5) | 13 (40.6) | 0.787 |
| Body mass index | 22.3 ± 2.1 | 21.9 ± 2.2 | 0.398 |
Percutaneous endoscopic gastrostomy;
Naso-gastric tube. Values are presented as number of patients or mean ± SD. WPF: Whole-protein formula; PEF: Dipeptide- and tripeptide-based enteral formula.
Differences in nutritional status between the whole-protein formula group and the dipeptide- and tripeptide-based formula group
| Albumin (g/dL) | |||
| POD | 2.59 ± 0.21 | 2.57 ± 0.19 | 0.652 |
| POD-5 | 2.60 ± 0.26 | 2.68 ± 0.28 | 0.198 |
| POD-10 | 2.70 ± 0.30 | 2.89 ± 0.27 | 0.010 |
| Prealbumin (mg/dL) | |||
| POD-1 | 11.1 ± 1.4 | 10.6 ± 1.3 | 0.201 |
| POD-5 | 11.6 ± 1.2 | 12.8 ± 2.1 | 0.006 |
| POD-10 | 12.9 ± 1.7 | 15.1 ± 1.5 | < 0.001 |
| TLC | |||
| POD-1 | 1069 ± 135 | 1077 ± 148 | 0.801 |
| POD-5 | 1082 ± 149 | 1192 ± 168 | 0.012 |
| POD-10 | 1231 ± 162 | 1311 ± 182 | 0.052 |
| CRP | |||
| POD-1 | 43.7 ± 7.8 | 43.0± 9.4 | 0.742 |
| POD-5 | 32.7 ± 4.9 | 33.4 ± 5.2 | 0.824 |
| POD-10 | 19.7 ± 5.0 | 18.5 ± 5.4 | 0.416 |
Postoperative day;
Total lymphocyte count;
C-reactive protein. Values are presented as mean ± SD. WPF: Whole-protein formula.
Clinical outcomes for the whole-protein formula group and the dipeptide- and tripeptide-based formula group
| Length of stay in the ICU | 6.8 ± 1.5 | 6.2 ± 0.8 | 0.047 |
| Maximum caloric intake during ICU stay (kcal/kg) | 22.5 ± 1.9 | 23.2 ± 2.4 | 0.063 |
| Caloric intake (kcal/kg body weight/d) | |||
| POD | 20.7 ± 2.3 | 21.5 ± 1.7 | 0.116 |
| POD-10 | 23.5 ± 2.4 | 25.1 ± 2.9 | 0.010 |
| Maximum GRV | 183.6 ± 88.0 | 138.0 ± 63.9 | 0.016 |
| Prevalence of suspended feeding due to high GRV (%) | 21.8 | 15.2 | 0.071 |
| Prevalence of diarrhea (%) | 19.9 | 13.2 | 0.056 |
| Prevalence of pneumonia (%) | 5 | 3.1 | 0.692 |
Intensive care unit;
Postoperative day;
Gastric residual volume. Values are presented as mean ± SD. WPF: Whole-protein formula.